Page results
-
The haematology and critical care services in our flagship University College Hospital Grafton Way Building are now open.
-
As World Lung Cancer Day approaches (1 August) the SUMMIT Study reports that it has made great strides in catching up with patients whose nodule follow ups were cancelled due to COVID-19.
-
This page has been written for parents, carers and family members who are acting as carers and comforters for children and young people having radioactive mIBG treatment.
-
Researchers at UCLH and Imperial College Healthcare NHS Trust are to trial a new weight loss treatment which involves reducing blood supply to part of the stomach.
-
Acute Myeloid Leukaemia (AML) is a form of cancer that develops in your bone marrow and affects your blood cells.
-
Your acute myeloid leukaemia (AML) treatment will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
Acute lymphoblastic leukaemia (ALL) is a form of cancer that affects the cells in the bone marrow, the soft material inside your bones.
-
Your treatment for acute lymphoblastic leukaemia (ALL) will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
This page tells you about the procedure known as a Bronchial Artery Embolisation (BAE).
-
UCLH is to host to a new collaboration researching patient safety, after being awarded £3million in funding.
File results
-
FOI2017266 Viscosupplementation injections
-
FOI2017263 Self-administration of medicines policies and carers policies
-
FOI2017295 A&E attendances for acopia
-
FOI2017296 Contracts for the redevelopment of the Middlesex annexe and Royal London Hospital for Integrated Medicine
-
FOI2017307 Televisions for patients
-
FOI2017314 Deep brain stimulation procedures
-
FOI2017300 Sustainability and transformation
-
FOI2017315 Expenditure on reconciliation and validation of incomplete and missing RTT codes
-
FOI2017320 Patients with Multiple Sclerosis treated with MS disease modifying drugs
-
FOI/2023/0226 - Treatment with Nivolumab